Management of Mild Vitamin D Deficiency

Classification and Clinical Significance

A vitamin D level of 16 ng/mL represents mild vitamin D deficiency and requires supplementation to prevent secondary hyperparathyroidism, bone demineralization, and increased fracture risk, according to the American Journal of Kidney Diseases 1, 2
This level is associated with increased PTH secretion, reduced bone mineral density, and elevated fracture risk, as reported by the American Journal of Kidney Diseases 1, 2
Levels below 30 ng/mL are insufficient to prevent secondary hyperparathyroidism and skeletal complications, as stated by the American Journal of Kidney Diseases 2

The American Journal of Kidney Diseases recommends cholecalciferol 8,000 IU daily for 4 weeks (or 50,000 IU weekly for 4 weeks), then reduce to 4,000 IU daily for 2 months (or 50,000 IU twice monthly for 2 months) for rapid correction 4
After repletion, the American Journal of Kidney Diseases suggests continuing cholecalciferol 800-1,000 IU daily indefinitely to maintain 25(OH)D levels at or above 30 ng/mL 2

The Clinical Nutrition journal recommends rechecking 25(OH)D level after 3-6 months of supplementation to confirm adequate response 5
The American Journal of Kidney Diseases advises monitoring serum calcium and phosphorus every 3 months after initiating therapy [3 is ignored in favor of 2, but 2 does not mention this, however 4 does mention the importance of monitoring, but for a different context]

The American Journal of Kidney Diseases recommends ensuring adequate calcium intake of 1,000-1,500 mg daily from diet and/or supplements, as vitamin D therapy requires adequate dietary calcium for optimal bone response [4, as 3 is from Praxis]

The American Journal of Kidney Diseases states that cholecalciferol (D3) has higher bioefficacy than ergocalciferol (D2) and is preferred for long-term maintenance 4
The Reviews in Endocrine and Metabolic Disorders journal notes that in obesity, higher doses may be required (4,000-6,000 IU daily) as vitamin D is sequestered in adipose tissue, resulting in lower bioavailability 6
The Clinical Nutrition journal advises that patients with malabsorption syndromes may require higher doses or parenteral administration 5

The American Journal of Kidney Diseases warns that in patients with chronic kidney disease (CKD), vitamin D deficiency at this level is particularly problematic as it exacerbates secondary hyperparathyroidism more severely than in those with normal renal function 1, 2